logo-loader
viewAstraZeneca

AstraZeneca’s severe asthma treatment granted breakthrough therapy designation

A breakthrough therapy designation is designed to expedite the development and review of medicines that are intended to treat a serious and have shown promise in early-stage clinical trials

lung x ray
An estimated 35mln people around the world suffer from severe asthma

AstraZeneca PLC’s (LON:AZN) tezepelumab severe asthma treatment has been granted breakthrough therapy designation by the US Food and Drug Administration.

A BTD is designed to expedite the development and review of medicines that are intended to treat a serious and have shown promise in early-stage clinical trials.

Tezepelumab was awarded the designation after data from a phase IIb trial showed a significant reduction in the annual asthma exacerbation rate compared with a placebo.

READ: Astra's lupus drug falls at final hurdle

Current treatments only target a certain subset of patients but Astra reckons its drug can treat all sufferers.

Tezepelumab, which is being developed in collaboration with Amgen Inc (NASDAQ:AMGN), is currently in the phase III PATHFINDER clinical trial programme.

Chief medical officer Sean Bohen said: “Tezepelumab is exciting because it has the potential to treat a broad population of severe asthma patients, including those ineligible for currently-approved biologic therapies.

“The Breakthrough Therapy Designation will help us bring tezepelumab to patients as quickly as possible.”

AstraZeneca shares edged 0.2% to 5,645p on Friday morning.

Quick facts: AstraZeneca

Price: 7275 GBX

LSE:AZN
Market: LSE
Market Cap: £95.44 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Iofina PLC's Tom Becker updates on Organic Vines investment and IO#8...

Iofina PLC's (LON:IOF) Tom Becker speaks to Proactive London's Andrew Scott soon after announcing their investment in Organic Vines - a hemp seed production and genetics firm. Becker says they're anticipating to turn a profit of US$1.8mln by mid-2020. He also updates on the construction of...

9 hours, 18 minutes ago

2 min read